Poolbeg Pharma CEO Jeremy Skillington and chairman Cathal Friel joined Proactive's Stephen Gunnion with an update on the clinical development progress of the company's lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.
Poolbeg telling Proactive that it intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in the molecule’s development. The company has signed a Letter of Intent to retain the Centre for Human Drug Research to run the challenge study and signed an agreement with SEDA Pharmaceutical Development Services for drug formulation services.
